Viking Therapeutics VKTX Cash Flow Statement (2014-2026)

NASDAQ VKTX
$28.44 -0.22 (-0.77%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Viking Therapeutics Quarterly Cash Flow Statement

Periods 51 quarters
Latest Sep 2026

Viking Therapeutics reported cash from operations of -$138.19M and free cash flow of -$138.19M for the quarter ended Sep 2026, down 47.0% year over year. This cash flow statement covers 51 quarters of results from Mar 2014 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-12.36M-16.10M-17.43M-15.77M-19.56M-19.53M-19.23M-22.53M-24.61M-27.36M-22.25M-24.94M-35.42M-45.63M-65.56M-90.79M-157.66M-158.33M-128.02M-183.19M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Share-based CompensationStock Comp.
1.43M2.36M2.22M1.94M2.16M3.57M4.62M4.48M4.08M7.98M7.08M8.98M5.67M11.35M13.55M7.34M8.59M10.34M11.13M17.89M
Gains from Investment SecuritiesGains Investment
-0.08M0.00M0.11M0.00M0.01M0.04M0.03M
Other non-cash itemsOther Non-Cash
-3.06M0.76M0.01M0.03M-1.18M0.11M0.03M0.00M0.11M0.11M0.02M0.02M0.15M0.15M0.02M0.01M0.08M0.09M
Change in Working Capital
Change in Account PayablesChange Payables
-1.39M1.71M2.95M-2.96M5.39M-4.73M1.81M0.10M1.80M-2.29M5.86M-10.84M9.56M-2.11M-2.21M-1.08M48.84M13.93M1.83M13.12M
Change in Accrued ExpensesChange Accrued Exp.
-1.08M0.69M0.52M2.10M2.49M-1.57M-3.99M-0.18M3.92M15.92M-13.55M11.28M-7.84M-5.74M14.64M-4.80M2.07M15.86M1.34M10.48M
Change in Other Operating AssetsOther Assets Change
-0.29M-0.13M2.30M-0.97M1.32M2.02M-7.28M-1.62M0.16M-2.40M0.24M1.38M-0.86M7.08M5.10M2.63M-14.69M-5.56M10.62M-4.18M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.09M-0.08M0.08M-0.11M-0.08M-0.09M-0.09M-0.09M-0.09M-0.09M-0.09M-0.10M-0.13M-0.13M-0.13M-0.13M-0.12M-0.14M-0.19M-0.14M
Other Working Capital ChangesOther WC Changes
0.20M0.05M-2.22M0.86M-1.40M-2.10M7.20M1.53M-0.25M2.32M-0.33M-1.48M0.73M-7.21M-5.23M-2.76M14.58M5.43M-10.81M4.04M
Cash from OperationsCash from Ops.
-12.35M-10.53M-13.44M-13.50M-10.93M-24.64M-11.44M-19.66M-17.64M-6.13M-28.51M-21.96M-31.18M-52.33M-47.06M-94.00M-85.29M-113.98M-125.17M-138.19M
Investing Activities
Purchase of InvestmentsInvestments Purchased
35.57M30.68M35.70M10.45M44.61M57.40M243.98M79.40M97.53M596.60M229.82M149.99M136.96M232.61M123.48M21.45M40.49M72.44M70.05M12.28M
Sale and Maturity of InvestmentsInvestments Sold
62.98M32.30M54.68M37.34M51.87M59.59M39.49M66.87M133.27M136.81M103.76M175.89M143.54M295.86M165.98M181.48M116.11M126.63M179.49M104.80M
Cash from Investing ActivitiesCash from Investing
27.41M1.62M18.98M26.89M7.26M2.20M-204.48M-12.53M35.73M-459.79M-126.06M25.90M6.58M63.25M42.51M160.03M75.61M54.19M109.43M92.52M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Net Long-Term Debt Issued (Repaid)Net LT Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
0.07M0.61M0.08M0.15M4.00M2.60M6.57M4.36M2.94M2.51M11.40M0.35M0.55M0.44M3.16M0.50M1.00M297.99M
Shares Repurchased
5.12M1.67M
Net Shares Issued and RepurchasedNet Shares Issued
0.07M-4.51M-1.59M0.15M4.00M2.60M6.57M4.36M2.94M2.51M11.40M0.35M0.55M0.44M3.16M0.50M1.00M297.99M
Net Equity Issued and RepurchasedNet Equity Issued
0.07M-5.12M-1.67M4.00M2.60M6.57M4.36M2.94M2.51M11.40M0.35M0.55M0.44M3.16M0.50M1.00M297.99M
Other financing activities (as filed)
-0.50M-1.03M-1.71M-5.41M-42.10M
Cash from Financing ActivitiesCash from Financing
0.05M-5.01M-1.59M0.01M10.75M4.18M267.08M-0.07M0.19M606.04M2.91M2.52M1.00M0.35M0.51M0.48M75.10M12.08M23.59M597.55M
Additional items
Exchange Rate EffectFX Effect
-0.22M0.14M-0.01M0.00M-0.07M0.05M-0.05M0.00M-0.03M-0.07M0.00M-0.01M-0.01M0.01M0.02M-0.03M
Change in Cash
15.11M-13.92M3.95M13.41M7.08M-18.26M51.16M-32.27M18.28M140.11M-151.67M6.46M-23.60M11.26M-4.05M66.50M65.43M-47.71M7.85M551.88M
Ending Cash Balance
26.37M12.45M16.23M29.41M36.63M18.36M69.52M37.19M55.52M195.58M43.92M50.35M26.68M37.94M33.88M100.38M165.81M118.12M125.96M677.81M
Free Cash FlowFCF
-12.35M-10.53M-13.44M-13.50M-10.93M-24.64M-11.44M-19.66M-17.64M-6.13M-28.51M-21.96M-31.18M-52.33M-47.06M-94.00M-85.29M-113.98M-125.17M-138.19M
Net Cash FlowNCF
15.11M-13.92M3.95M13.41M7.08M-18.26M51.16M-32.27M18.28M140.11M-151.67M6.46M-23.60M11.26M-4.05M66.50M65.43M-47.71M7.85M551.88M

Viking Therapeutics Cash Flow Statement API

Pull Viking Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=VKTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY